Karbapenemlere Direnç Mekanizmaları

Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a system analysis. Lancet. 2022;399: 629-655. doi: 10.1016/S0140-6736(21)02724-0

Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clinical Infectious Diseases. 2022;75(2): 187-212. doi:10.1093/cid/ciac268

3. World Health Organization. WHO publishes list of bacteria for which new antibiotics are urgently needed. Avaliable from: https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed (Accessed 17th November 2022).

World Health Organization Regional Office for Europe/European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2022 – 2020 data. Copenhagen: WHO Regional Office for Europe; 2022. Avaliable from: https://www.ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe-2022-2020-data (Accessed 17th November 2022)

Aurilio C, Sansone P, Barbarisi M, et al. Mechanisms of Action of Carbapenem Resistance. Antibiotics. 2022;11: 421. doi: 10.3390/antibiotics11030421

Ghai I, Ghai S. Understanding antibiotic resistance via outer membrane permeability. Infection and Drug Resistance. 2018;11: 523-530. doi: 10.2147/IDR.S156995

Tenover FC, Nicolaub DP, Gil CM. Carbapenemase-producing Pseudomonas aeruginosa –an emerging challenge. Emerging Microbes & Infections. 2022; 11: 811-814. doi: 10.1080/22221751.2022.2048972

Li XZ, Plésiat P, Nikaido H. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clinical Microbiology Reviews. 2015;28(2): 337-418. doi: 10.1128/CMR.00117-14

Abdi SN, Ghotaslou R, Ganbarov K, et al. Acinetobacter baumannii Efflux Pumps and Antibiotic Resistance. Infection and Drug Resistance. 2020;13: 423-434. doi: 10.2147/IDR.S228089

AlMatar M, Albarri O, Makky EA, et al. Efflux pump inhibitors: new updates. Pharmacological Reports. 2021;73(1): 1-16. doi: 10.1007/s43440-020-00160-9

Partridge SR, Kwong SM, Firth N, et al. Mobile Genetic Elements Associated with Antimicrobial Resistance. Clinical Microbiology Reviews. 2018;31(4): e00088-17. doi: 10.1128/CMR.00088-17.

Aslam B, Rasool M, Muzammil S, et al. (2020). Carbapenem Resistance: Mechanisms and Drivers of Global Menace. In S. Kırmusaoğlu, & S. B. Bhardwaj (Eds.), Pathogenic Bacteria. IntechOpen; 2020. Avaliable from; https://doi.org/10.5772/intechopen.90100 (Accessed 17th November 2022)

European Society of Clinical Microbiology and Infectious Diseases. EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. 2017. Avaliable from; https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_resistance_mechanisms_170711.pdf (Accessed 17th November 2022)

Codjoe FS, Donkor ES. Carbapenem Resistance: A Review. Medical Sciences (Basel). 2017;21; 6(1):1. doi: 10.3390/medsci6010001

Ambler RP. The structure of beta-lactamases. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 1980;289(1036): 321-331. doi: 10.1098/rstb.1980.0049

Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrobial Agents and Chemotherapy. 2010;54(3): 969-976. doi: 10.1128/AAC.01009-09

Iraz M, Duzgun AO, Cicek AC, et al. Characterization of novel VIM carbapenemase, VIM-38, and first detection of GES-5 carbapenem-hydrolyzing β-lactamases in Pseudomonas aeruginosa in Turkey. Diagnostic Microbiology and Infectious Disease. 2014;78: 292-294. doi: 10.1016/j.diagmicrobio.2013.12.003

Tamma PD, Goodman KE, Harris AD, et al. Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia. Clinical Infectious Diseases. 2017;64(3): 257–264. doi: 10.1093/cid/ciw741

Shields RK, Doi Y. Aztreonam Combination Therapy: An Answer to Metallo-β-Lactamase-Producing Gram-Negative Bacteria? Clinical Infectious Diseases. 2020;71(4): 1099-1101. doi: 10.1093/cid/ciz1159

Deshpande LM, Jones RN, Fritsche TR, et al. Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004). Microbial Drug Resistance. 2006;12(4): 223-230. doi: 10.1089/mdr.2006.12.223

Lauretti L, Riccio ML, Mazzariol A, et al. Cloning and characterization of blaVIM, a new integron-borne metallo-beta-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrobial Agents and Chemotherapy. 1999;43(7): 1584-1590. doi: 10.1128/AAC.43.7.1584

Riccio ML, Franceschini N, Boschi L, et al. Characterization of the metallo-beta-lactamase determinant of Acinetobacter baumannii AC-54/97 reveals the existence of bla(IMP) allelic variants carried by gene cassettes of different phylogeny. Antimicrobial Agents and Chemotherapy. 2000;44(5): 1229-1235. doi: 10.1128/AAC.44.5.1229-1235.2000

Marra AR, Pereira CA, Gales AC, et al. Bloodstream infections with metallo-beta-lactamase-producing Pseudomonas aeruginosa: epidemiology, microbiology, and clinical outcomes. Antimicrobial Agents and Chemotherapy. 2006;50(1): 388-390. doi: 10.1128/AAC.50.1.388-390.2006

Castanheira M, Toleman MA, Jones RN, et al. Molecular characterization of a beta-lactamase gene, blaGIM-1, encoding a new subclass of metallo-beta-lactamase. Antimicrobial Agents and Chemotherapy. 2004;48(12): 4654-4661. doi: 10.1128/AAC.48.12.4654-4661.2004

Lee K, Yum JH, Yong D, et al. Novel acquired metallo-beta-lactamase gene, bla(SIM-1), in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea. Antimicrobial Agents and Chemotherapy. 2005;49(11): 4485-4491. doi: 10.1128/AAC.49.11.4485-4491.2005

Nordmann P, Poirel L, Toleman MA, et al. Does broad-spectrum beta-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria? Journal of Antimicrobial Chemotherapy. 2011;66(4): 689-692. doi: 10.1093/jac/dkq520

Khan AU, Nordmann P. Spread of carbapenemase NDM-1 producers: the situation in India and what may be proposed. Scandinavian Journal of Infectious Diseases. 2012;44(7): 531-535. doi: 10.3109/00365548.2012.669046

Evans BA, Amyes SG. OXA β-lactamases. Clinical Microbiology Reviews. 2014;27(2): 241-263. doi: 10.1128/CMR.00117-13

Carrër A, Poirel L, Yilmaz M, et al. Spread of OXA-48-encoding plasmid in Turkey and beyond. Antimicrobial Agents and Chemotherapy. 2010;54(3): 1369-1373. doi: 10.1128/AAC.01312-09.

Ahmed SS, Alp E, Ulu-Kilic A, et al. Spread of carbapenem-resistant international clones of Acinetobacter baumannii in Turkey and Azerbaijan: a collaborative study. European Journal of Clinical Microbiology & Infectious Diseases. 2016;35(9):1463-1468. doi: 10.1007/s10096-016-2685-x

Kong KF, Jayawardena SR, Del Puerto A, et al. Characterization of poxB, a chromosomal-encoded Pseudomonas aeruginosa oxacillinase. Gene. 2005;358: 82-92. doi: 10.1016/j.gene.2005.05.027

Ryan MP, Pembroke JT, Adley CC. Ralstonia pickettii: a persistent gram-negative nosocomial infectious organism. Journal of Hospital Infection. 2006;62(3): 278-284. doi: 10.1016/j.jhin.2005.08.015.

Ambrose M, Malley RC, Warren SJC, et al. Pandoraea pnomenusa Isolated from an Australian Patient with Cystic Fibrosis. Frontiers in Microbiology. 2016;7: 692. doi: 10.3389/fmicb.2016.00692

Yahav D, Giske CG, Gramatniece A, et al. New β-lactam–β-lactamase inhibitor combinations. Clinical Microbiology Reviews. 2021;34: e00115-20. doi: 10.1128/CMR.00115-20

Lupia T, Corcione S, Shbaklo N, etal. Meropenem/Vaborbactam and Cefiderocol as Combination or Monotherapy to Treat Multi-Drug Resistant Gram-Negative Infections: A Regional Cross-Sectional Survey from Piedmont Infectious Disease Unit Network (PIDUN). Journal of Functional Biomaterials. 2022;13: 174. doi: 10.3390/jfb13040174

Gaibani P, Giani T, Bovo F, et al. Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing. Antibiotics. 2022;11: 628. doi: 10.3390/antibiotics11050628

Hujer AM, Bethel CR, Taracila MA, et al. Imipenem/Relebactam Resistance in Clinical Isolates of Extensively Drug Resistant Pseudomonas aeruginosa: Inhibitor-Resistant β-Lactamases and Their Increasing Importance. Antimicrobial Agents and Chemotherapy. 2022;66(5): e0179021. doi: 10.1128/aac.01790-21

Gaibani P, Bianco G, Amadesi S, et al. Increased blaKPC Copy Number and OmpK35 and OmpK36 Porins Disruption Mediated Resistance to Imipenem/Relebactam and Meropenem/Vaborbactam in a KPC-Producing Klebsiella pneumoniae Clinical Isolate. Antimicrobial Agents and Chemotherapy. 2022;66(5): e0019122. doi: 10.1128/aac.00191-22

Carattoli A, Arcari G, Bibbolino G, et al. Evolutionary Trajectories toward Ceftazidime-Avibactam Resistance in Klebsiella pneumoniae Clinical Isolates. Antimicrobial Agents and Chemotherapy. 2021;65(10): e0057421. doi: 10.1128/AAC.00574-21

Hernández-García M, Castillo-Polo JA, Cordero DG, et al. Impact of Ceftazidime-Avibactam Treatment in the Emergence of Novel KPC Variants in the ST307-Klebsiella pneumoniae High-Risk Clone and Consequences for Their Routine Detection. Journal of Clinical Microbiology. 2022;60(3): e0224521. doi: 10.1128/jcm.02245-21

World Health Organization. Surveillance of antimicrobial resistance in Europe, 2021 data. Avaliable from: https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2021-data (Accessed 1st December 2022).

Organisation for Economic Co-operation and Development. Antimicrobial Resistance Tackling the Burden in the European Union. Avaliable from: https://www.oecd.org/health/health-systems/AMR-Tackling-the-Burden-in-the-EU-OECD-ECDC-Briefing-Note-2019.pdf (Accessed 1st December 2022).

Gales AC, Seifert H, Gur D, Castanheira M, Jones RN, Sader HS. Antimicrobial susceptibility of Acinetobacter calcoaceticus–Acinetobacter baumannii complex and Stenotrophomonas maltophilia clinical isolates: results from the SENTRY Antimicrobial Surveillance Program (1997–2016). Open forum infectious diseases. 2019;6(1): 34–46. doi: 10.1093/ofid/ofy293

Nordmann P, Poirel L. Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria. Clinical Infectious Diseases. 2019;69(7): 521-528. doi: 10.1093/cid/ciz824

World Health Organization. Central Asian and Eastern European Surveillance of Antimicrobial Resistance: Annual report 2016. Avaliable from: https://www.euro.who.int/__data/assets/pdf_file/0009/323568/CAESAR-Annual-report-2016.pdf (Accessed 1st December 2022).

World Health Organization. Central Asian and Eastern European Surveillance of Antimicrobial Resistance: Annual report 2018. Avaliable from: https://apps.who.int/iris/handle/10665/324806 (Accessed 1st December 2022).

World Health Organization. Antimicrobial resistance surveillance in Europe 2022 – 2020 data. Avaliable from: https://apps.who.int/iris/handle/10665/351141 (Accessed 1st December 2022).

Aydın M, Azak E, Bilgin H, et al. Changes in antimicrobial resistance and outcomes of health care-associated infections. European Journal of Clinical Microbiology & Infectious Diseases. 2021;40(8): 1737-1742. doi: 10.1007/s10096-020-04140-y

Ergönül Ö, Aydin M, Azap A, et al. Healthcare-associated Gram-negative bloodstream infections: antibiotic resistance and predictors of mortality. The Journal of Hospital Infection. 2016;94(4): 381-385. doi:10.1016/j.jhin.2016.08.012

Ergonul O, Tokca G, Keske Ş, et al. Elimination of healthcare-associated Acinetobacter baumannii infection in a highly endemic region. International Journal of Infectious Diseases. 2022;114: 11-14. doi: 10.1016/j.ijid.2021.10.011

Akkaya Isik S, Yenilmez E, Cetinkaya RA, et al. A meta-analysis of antibiotic resistance rates in Pseudomonas aeruginosa isolated in blood cultures in Turkey between 2007 and 2017. Northern Clinics Of Istanbul. 2021;8(3): 286–297. doi: 10.14744/nci.2020.93195

Agyeman AA, Bergen PJ, Rao GG, et al. Mortality, clinical and microbiological response following antibiotic therapy among patients with carbapenem-resistant Klebsiella pneumoniae infections (a meta-analysis dataset). Data in Brief. 2020;20: 104907. doi: 10.1016/j.ijantimicag.2019.10.014

Vatansever C, Menekse S, Dogan O, et al. Co-existence of OXA-48 and NDM-1 in colistin resistant Pseudomonas aeruginosa ST235. Emerging Microbes & Infections. 2020;9(1): 152-154. doi: 10.1080/22221751.2020.1713025

Boral B, Unaldi Ö, Ergin A. et al. A prospective multicenter study on the evaluation of antimicrobial resistance and molecular epidemiology of multidrug-resistant Acinetobacter baumannii infections in intensive care units with clinical and environmental features. Annals of Clinical Microbiology and Antimicrobials. 2019;18: 19. doi: 10.1186/s12941-019-0319-8

Al-Zahrani İA. Routine detection of carbapenem-resistant gram-negative bacilli in clinical laboratories. Saudi Medical Journal. 2018;39 (9): 861-872. doi: 10.15537/smj.2018.9.22840

Brolund A, Lagerqvist N, Byfors S, et al. Worsening epidemiological situation of carbapenemase-producing Enterobacteriaceae in Europe, assessment by national experts from 37 countries, July 2018. Euro Surveillance. 2019;24(9): pii=1900123. doi: 10.2807/1560-7917.ES.2019.24.9.1900123

Ludden C, Lötsch F, Alm E, et al. Cross-border spread of blaNDM-1- and blaOXA-48-positive Klebsiella pneumoniae: a European collaborative analysis of whole genome sequencing and epidemiological data, 2014 to 2019. Euro Surveillance. 2020;25(20):pii=2000627. doi: org/10.2807/1560-7917.ES.2020.25.20.2000627

Neidhöfer C, Buechler C, Neidhöfer G, et al. Global Distribution Patterns of CarbapenemaseEncoding Bacteria in a New Light: Clues on a Role for Ethnicity. Frontiers in Cellular and Infection Microbiology. 2021;11: 659753. doi: 10.3389/fcimb.2021.659753

Han R, Shi Q, Wu S, et al. Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) Among Carbapenem-Resistant Enterobacteriaceae Isolated From Adult and Children Patients in China. Frontiers in Cellular Infection Microbiology. 2020;10:314. doi: 10.3389/fcimb.2020.00314

Karlowsky JA, Bouchillon SK, El Mahdy Kotb R, et al. Carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa causing infection in Africa and the Middle East: a surveillance study from the ATLAS programme (2018-20). JAC-Antimicrobial Resistance. 2022;4(3): dlac060. doi: 10.1093/jacamr/dlac060

Köle M, Sesli Çetin E, Şirin MC, et al. Seftazidim-Avibaktam, Meropenem ve Kolistinin Tek Başına ve İkili Kombinasyonlarının Çeşitli Klinik Örneklerden İzole Edilen Karbapenem Dirençli Klebsiella pneumoniae Suşlarına Karşı In Vitro Etkinliğinin Araştırılması. Mikrobiyoloji Bülteni. 2022;56(2): 230-250. doi: 10.5578/mb.20229804

Hortaç İştar E, Alışkan HE, Göçmen JS. Diverse efficacy of CarbaNP test among OXA-48 carbapenemase producing Enterobacterales in an endemic region. Acta Microbiologica et Immunologica Hungarica. 2021;68(1): 34-39. doi: 10.1556/030.2021.01220

Süzük Yıldız S, Şimşek H, Bakkaloğlu Z, et al. Türkiye’de 2019 Yılı İçinde İzole Edilen Escherichia coli ve Klebsiella pneumoniae İzolatlarında Karbapenemaz Epidemiyolojisi. Mikrobiyoloji Bülteni. 2021;55(1): 1-16. doi: 10.5578/mb.20124

Hazırolan G, Karagöz A. Emergence of carbapenemase-producing and colistin resistant Klebsiella pneumoniae ST101 high-risk clone in Turkey. Acta Microbiologica et Immunologica Hungarica. 2020;67(4): 216–221. doi: 10.1556/030.2020.01275

Sağıroğlu P, Hasdemir U, Altınkanat Gelmez G, et al. Performance of "RESIST-3 O.K.N. K-SeT" immunochromatographic assay for the detection of OXA-48 like, KPC, and NDM carbapenemases in Klebsiella pneumoniae in Turkey. Brazilian Journal of Microbiology. 2018;49(4): 885-890. doi: 10.1016/j.bjm.2018.02.002

Cizmeci Z, Aktas E, Otlu B, et al. Molecular characterization of carbapenem- resistant Enterobacteriaceae yields increasing rates of NDM-1 carbapenemases and colistin resistance in an OXA-48- endemic area. Journal of Chemotherapy. 2017;29(6): 344-350. doi: 10.1080/1120009X.2017.1323149

Erdem F, Oncul O, Aktas Z. Characterization of Resistance Genes and Polymerase Chain Reaction-Based Replicon Typing in Carbapenem-Resistant Klebsiella pneumoniae. Microbial Drug Resistance. 2019;25(4): 551-557. doi: 10.1089/mdr.2018.0231

Çakar A, Akyön Y, Gür D, et al. Türkiye'de 2014 yılı içinde izole edilen karbapeneme dirençli Escherichia coli ve Klebsiella pneumoniae izolatlarında karbapenemaz varlığının araştırılması. Mikrobiyoloji Bülteni. 2016;50(1): 21-33. doi: 10.5578/mb.10695

Alp E, Perçin D, Colakoğlu S, et al. Molecular characterization of carbapenem-resistant Klebsiella pneumoniae in a tertiary university hospital in Turkey. Journal of Hospital Infections. 2013;84(2): 178-180. doi: 10.1016/j.jhin.2013.03.002

Kutlu HH, Us E, Tekeli A. Bir üniversite hastanesinde 2010-2014 yılları arasında izole edilen Enterobacteriaceae türlerinin karbapenemaz genlerinin araştırılması ve moleküler epidemiyolojisinin belirlenmesi. Mikrobiyoloji Bülteni. 2018;52(1): 1-12. doi: 10.5578/mb.66156

Gozalan A, Unaldı O, Guldemir D, et al. Molecular Characterization of Carbapenem-Resistant Acinetobacter baumannii Blood Culture Isolates from Three Hospitals in Turkey. Japanese Journal of Infectious Diseases. 2021;74(3): 200-208. doi: 10.7883/yoken.JJID.2020.478

Davandeh I, Eraç B, Aydemir SŞ. Investigation of class-d beta-lactamases causing carbapenem resistance in clinical Acinetobacter baumannii isolates. Turkish Journal of Medical Sciences. 2017;47(5): 1661-1666. doi: 10.3906/sag-1607-91

Çekin ZK, Dabos L, Malkoçoğlu G, et al. Carbapenemase -producing Pseudomonas aeruginosa isolates from Turkey: First report of P. aeruginosa high-risk clones with VIM-5- and IMP-7- type carbapenemases in a tertiary hospital. Diagnostic Microbiology and Infectious Disease. 2021;99(1): 115174. doi. 10.1016/j.diagmicrobio.2020.115174

Malkoçoğlu G, Aktaş E, Bayraktar B, et al. VIM-1, VIM-2, and GES-5 Carbapenemases Among Pseudomonas aeruginosa Isolates at a Tertiary Hospital in Istanbul, Turkey. Microbial Drug Resistance. 2017;23(3): 328-334. doi: 10.1089/mdr.2016.0012

Çopur Çiçek A, Ertürk A, Ejder N, et al Screening of Antimicrobial Resistance Genes and Epidemiological Features in Hospital and Community-Associated Carbapenem-Resistant Pseudomonas aeruginosa Infections. Infection and Drug Resistance. 2021;14: 1517-1526. doi: 10.2147/IDR.S299742